Chardan Capital Reiterates Buy on Dyne Therapeutics, Maintains $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Dyne Therapeutics (NASDAQ:DYN) and maintained a price target of $20.
August 04, 2023 | 2:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Dyne Therapeutics and maintained a price target of $20.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Dyne Therapeutics. The maintained price target of $20 suggests that the analyst believes the stock is undervalued at current levels. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100